Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6373
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 December 2025 | Pending further discussion with the company, the timelines for this appraisal are now to be confirmed. We are unable to provide a revised timeline at this time as the company is currently evaluating its plans for a submission. Submissions are no longer required by 3 December 2025, and the committee meeting scheduled for 12 May 2026 will not take place. We will write to you when a new submission deadline and updated timelines are confirmed. |
| 30 September 2025 | Invitation to participate |
| 25 October 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2025. |
| 11 June 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-November 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2025. |
| 25 April 2024 - 24 May 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373 |
| 25 April 2024 | In progress. Scoping commencing |
| 25 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 25 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual